Testosterone Enanthate Compassionate Use and Expanded Access

What "Compassionate Use" and "Expanded Access" Actually Mean for Testosterone Enanthate

The FDA's expanded access program (also called compassionate use) allows patients to receive investigational or otherwise inaccessible drugs outside a clinical trial. For testosterone enanthate specifically, this pathway is rarely necessary because FDA-approved generic formulations are commercially available at low cost. Still, understanding the pathway matters for edge cases.

The legal framework is 21 CFR Part 312 Subpart I, which the FDA published guidance on most recently in 2016. Three tiers exist: single-patient access, intermediate-size population access, and widespread treatment IND. FDA expanded access regulations require a licensed physician to submit a request and, for single-patient cases, most requests receive a response within 24 hours.

When a Patient Might Actually Need Expanded Access for Testosterone Enanthate

Expanded access for TE is most relevant in four scenarios:

1. A patient is enrolled in a clinical trial studying a novel testosterone formulation and the trial closes before treatment completion.
2. A documented shortage of FDA-approved testosterone enanthate affects supply at compounding pharmacies or retail distributors.
3. A patient in a country without commercial TE availability seeks access through a US-based compassionate use mechanism.
4. A pediatric patient with documented hypogonadotropic hypogonadism requires a dose or formulation not commercially available.

The FDA's Office of Oncology Products processes most compassionate use requests, but endocrinology-related requests route through the Office of Specialty Medicine. Physicians can call the FDA's expanded access call center at 1-855-543-3784 for same-day guidance.

The Single-Patient IND Process Step by Step

A physician initiating a single-patient IND for testosterone enanthate must submit FDA Form 3926, a brief clinical protocol, and an IRB notification (or waiver for life-threatening cases). The FDA has a statutory 30-day review period but typically responds within 1 to 3 business days for urgent requests. FDA guidance on individual patient expanded access specifies that the physician assumes responsibility for informed consent and adverse event reporting under 21 CFR 312.310.

FDA Approval Status and Labeled Indications for Testosterone Enanthate

Testosterone enanthate has carried FDA approval since 1953 under the brand name Delatestryl. The current FDA prescribing information for Delatestryl lists approved indications as: primary hypogonadism (congenital or acquired), hypogonadotropic hypogonadism (congenital or acquired), and delayed puberty in males. Gender-affirming hormone therapy is an off-label but widely accepted and guideline-supported use.

Hypogonadism Diagnosis Requirements

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy, published in the Journal of Clinical Endocrinology and Metabolism, recommends diagnosing hypogonadism only when a patient has both consistent signs and symptoms AND unequivocally low serum testosterone measured on at least two morning samples. The guideline states: "We recommend against starting testosterone therapy in patients who have normal serum testosterone concentrations." This requirement directly affects expanded access eligibility, because FDA compassionate use requests must document a legitimate unmet medical need.

Off-Label Uses Supported by Guidelines

The World Professional Association for Transgender Health (WPATH) Standards of Care Version 8, published in 2022, supports testosterone therapy for transmasculine individuals. Testosterone enanthate is one of the most commonly used formulations in gender-affirming care, typically dosed at 25 to 100 mg IM weekly or 50 to 200 mg every two weeks. For this population, commercial access rather than expanded access is the appropriate pathway in most US states.

How to Get Testosterone Enanthate Cheaper: A Practical Cost Map

Cost is the primary barrier to testosterone enanthate access for uninsured or underinsured patients. The strategies below are ranked from lowest to highest complexity.

Generic Formulations and Cash Pricing

Multiple generic manufacturers produce testosterone enanthate 200 mg/mL solution for injection. Hikma Pharmaceuticals, West-Ward (a Hikma subsidiary), and Pfizer's Greenstone unit all hold ANDA approvals visible on the FDA's Orange Book. At warehouse pharmacies such as Costco, a 10 mL multi-dose vial (2,000 mg total testosterone enanthate) costs approximately $55, $75 cash, equivalent to a 5 to 10 month supply for a patient on 100 to 200 mg weekly dosing.

GoodRx coupons at major chains bring single 1 mL vials (200 mg/mL) to $28, $45 depending on pharmacy and ZIP code. These coupons are accessible at goodrx.com and are compatible with generic dispensing only. Brand-name Delatestryl is rarely dispensed in 2026; the cost differential versus generic is not clinically meaningful.

Xyosted Manufacturer Savings Card

Antares Pharma's Xyosted (testosterone enanthate 50 mg, 75 mg, or 100 mg subcutaneous autoinjector) targets patients who prefer a once-weekly subcutaneous injection. Commercially insured patients may pay as little as $0/month with the manufacturer savings card. Uninsured patients do not qualify for the savings card but may access the Antares patient assistance program with income-based eligibility thresholds. Xyosted's subcutaneous formulation has a distinct pharmacokinetic profile from IM testosterone enanthate: a 2020 study in Andrology (N=150) showed stable trough testosterone levels with less peak-to-trough variability than conventional IM injection.

Compounding Pharmacy Options

FDA-registered 503A compounding pharmacies can prepare testosterone enanthate in customized concentrations (e.g., 200 mg/mL in cottonseed or sesame oil) when a licensed prescriber documents a patient-specific clinical need. Compounded TE is not FDA-approved but is legal under the FD&C Act Section 503A. Costs at reputable 503A pharmacies typically range from $40, $90 per 10 mL vial. 503B outsourcing facilities, regulated under stricter FDA oversight, may also supply testosterone enanthate to clinics in bulk. The FDA maintains a list of registered 503B outsourcing facilities updated quarterly.

A 2019 JAMA Internal Medicine analysis found that compounded testosterone products vary in actual concentration by up to 16% from labeled content, a consideration that prescribers should discuss with patients when switching from FDA-approved generics to compounded formulations.

Can I Use HSA or FSA for Testosterone Enanthate?

Yes. Prescribed testosterone enanthate qualifies as a medical expense under IRS Publication 502. IRS Publication 502 (2024) defines eligible medical expenses as amounts paid for the "diagnosis, cure, mitigation, treatment, or prevention of disease." A physician's prescription converts testosterone enanthate from a personal expense to a qualified medical expense eligible for HSA and FSA reimbursement.

HSA Reimbursement Mechanics

Health Savings Accounts (HSAs) are funded with pre-tax dollars and have no use-it-or-lose-it restriction, making them particularly useful for ongoing TRT costs. In 2025, the IRS contribution limit is $4,300 for self-only coverage and $8,550 for family coverage under a high-deductible health plan (HDHP). IRS Revenue Procedure 2024-25 sets the 2025 HDHP minimums at $1,650 (self) and $3,300 (family).

Testosterone enanthate vials, syringes, and needles for self-injection are all HSA/FSA eligible when the prescription covers the medication and the physician's plan of care documents the injection supplies. The IRS FAQ on HSA-eligible expenses confirms that prescription drugs dispensed by a licensed pharmacist qualify.

FSA Considerations for TRT Patients

Flexible Spending Accounts cover the same expense categories as HSAs but require annual election with a "use it or lose it" deadline (with a $640 rollover allowed for 2024 plan years under IRS Notice 2023-75). Patients who know their annual testosterone enanthate consumption can plan FSA elections precisely. At $55 per 10 mL multi-dose vial used over 10 months, a patient on 100 mg/week would spend approximately $66, $75/year on the drug alone, well within FSA limits.

Insurance Coverage and Prior Authorization for Testosterone Enanthate

Most commercial insurance plans cover generic testosterone enanthate on Tier 1 or Tier 2 formularies when the diagnosis code is E29.1 (testicular hypofunction) or, less commonly, E23.0 (hypopituitarism). Prior authorization is required by approximately 40% of commercial plans according to a 2022 survey published in Urology, which analyzed coverage policies for testosterone replacement across 50 payer plans.

Prior Authorization Documentation Checklist

Physicians requesting prior authorization for testosterone enanthate typically need:

• Two morning serum total testosterone levels below the laboratory's reference range (generally <300 ng/dL per Endocrine Society guidelines)
• Documentation of signs and symptoms consistent with hypogonadism (decreased libido, fatigue, loss of muscle mass, or bone density decline)
• A note that the patient has been counseled on fertility implications, as testosterone suppresses endogenous spermatogenesis via HPG axis suppression (Ramasamy et al., Fertil Steril 2014)
• ICD-10 diagnosis code on the prior auth form matching the medication's labeled indication

Medicare and Medicaid Coverage

Medicare Part D plans cover testosterone enanthate generics; formulary placement varies by plan. Patients should use the Medicare Plan Finder to identify plans with Tier 1 testosterone enanthate placement. Medicaid coverage is state-dependent. Most state Medicaid programs cover testosterone for documented hypogonadism, but prior authorization requirements and quantity limits are stricter than commercial plans. Gender-affirming hormone therapy coverage through Medicaid is expanding after the 2022 HHS Notice of Benefit and Payment Parameters, though individual state policies vary significantly.

Patient Assistance Programs for Testosterone Enanthate

No major pharmaceutical manufacturer currently offers a patient assistance program (PAP) specifically for generic testosterone enanthate, because generic pricing is already at or near the cost-floor for controlled substances at most pharmacies. The PAP field for TE is therefore focused on branded and specialty formulations:

Xyosted (Antares Pharma). The Xyosted savings program provides eligible commercially insured patients with co-pay assistance capped at $200/month. Uninsured patients with household incomes at or below 400% of the federal poverty level may qualify for free product through the manufacturer's patient support program.

NeedyMeds Database. The NeedyMeds.org database aggregates disease-specific assistance programs, clinic-based free drug programs, and state pharmaceutical assistance programs that may cover testosterone enanthate for low-income patients.

340B Drug Pricing Program. Patients receiving care at Federally Qualified Health Centers (FQHCs) or other 340B-covered entities may access testosterone enanthate at significantly reduced acquisition costs passed through to the patient. The HRSA 340B program database allows patients to identify eligible providers by ZIP code.

A 2021 Health Affairs analysis of 340B program utilization found that safety-net hospitals and FQHCs serving high proportions of low-income patients dispensed substantially higher volumes of hormonal therapies at reduced cost, supporting the 340B pathway as a meaningful access mechanism for TRT patients without insurance.

Testosterone Enanthate in Clinical Trials: How to Access Investigational Protocols

Patients seeking testosterone enanthate as part of an investigational protocol (for indications beyond current FDA labeling) should search ClinicalTrials.gov using the MeSH term "testosterone enanthate." As of early 2026, active or recently completed trials include studies examining TE in male contraception, anemia of chronic kidney disease, and HIV-associated muscle wasting.

Male Contraception Research

The most extensively studied off-label use of testosterone enanthate is hormonal male contraception. The WHO/UNDP/UNFPA/World Bank Special Programme conducted a landmark trial (N=399 men) demonstrating that weekly IM testosterone enanthate 200 mg suppressed spermatogenesis to azoospermia or severe oligospermia in 98.6% of participants. Men enrolled in active male contraception trials can access testosterone enanthate at no cost through the trial protocol and may qualify for compassionate use continuation after trial closure if no commercial alternative exists.

Accessing Trial-Related TE After Study Closure

When a clinical trial involving testosterone enanthate closes before a participant completes treatment, the sponsoring investigator can apply for a single-patient expanded access IND under 21 CFR 312.310 to continue therapy. The treating physician must document that discontinuation would pose undue risk to the patient, a standard easily met for patients on chronic testosterone replacement.

Monitoring Requirements and Safety Considerations That Affect Access Decisions

Access decisions, whether through insurance, expanded access, or cash pay, should always include a monitoring plan. The Endocrine Society's 2018 guideline recommends checking serum testosterone 3 to 6 months after initiating therapy, then annually once stable. For IM testosterone enanthate, blood draws should be timed to mid-cycle (approximately 7 days after injection for a 14-day cycle) to capture a representative concentration rather than a peak or trough value.

Hematocrit Monitoring

Testosterone enanthate stimulates erythropoiesis. The Endocrine Society guideline recommends checking hematocrit at baseline, 3 to 6 months, and then annually. If hematocrit exceeds 54%, dose reduction or temporary discontinuation is indicated per guideline. Bachman et al. (JCEM 2010) demonstrated a dose-dependent increase in hematocrit with IM testosterone, with higher doses (>150 mg/week) producing greater erythrocytic stimulation.

Cardiovascular Monitoring

The FDA added a class warning in 2015 regarding cardiovascular risk with testosterone products, though this warning was directed primarily at use in men with age-related rather than pathological hypogonadism. The TRAVERSE trial (N=5,246, published NEJM 2023) provided the most definitive data to date: testosterone replacement in men 45 to 80 years with hypogonadism and cardiovascular risk factors did not increase the rate of major adverse cardiovascular events compared to placebo (hazard ratio 0.96; 95% CI 0.78 to 1.17) over a median follow-up of 33 months, though a higher rate of atrial fibrillation, acute kidney injury, and pulmonary embolism was observed in the testosterone group.

PSA Monitoring in Older Men

For men over age 40 initiating testosterone enanthate, the Endocrine Society recommends a digital rectal exam and PSA at baseline and 3 to 12 months after initiation. Rhoden and Morgentaler (NEJM 2004) reviewed the evidence on testosterone and prostate risk, concluding that there is no compelling evidence that testosterone therapy increases prostate cancer risk in men with normal baseline PSA, though prostate cancer remains an absolute contraindication to testosterone therapy.

Telehealth Prescribing of Testosterone Enanthate in 2026

Testosterone enanthate is a Schedule III controlled substance under the Controlled Substances Act. The DEA's 2023 proposed rule on telemedicine prescribing of controlled substances, finalized with modifications in 2024, established that Schedule III non-narcotic substances (which includes testosterone) may be prescribed via telemedicine after an audio-video visit with a registered DEA practitioner, provided the patient is located in a state that permits such prescribing and the prescriber holds a DEA registration valid in that state.

The DEA telemedicine regulations at 21 CFR Part 1307 specify that the prescription must be transmitted electronically to a DEA-registered pharmacy. Patients using telehealth platforms such as HealthRX to access testosterone enanthate therapy should confirm that their prescribing clinician holds an active DEA registration and that their state does not impose additional restrictions on controlled substance telemedicine prescribing beyond federal minimums.

A 2023 JAMA Network Open study found that telemedicine-initiated testosterone prescriptions increased 52% between 2020 and 2022, with the majority of new prescriptions written by primary care physicians rather than endocrinologists or urologists, a shift that highlights both expanded access and the need for standardized monitoring protocols.

Practical Steps to Reduce Out-of-Pocket Costs Starting Today

The following sequence applies to a patient newly prescribed testosterone enanthate who wants to minimize cost:

1. Ask the prescriber to specify "testosterone enanthate 200 mg/mL injection, generic" on the prescription to ensure DAW-0 (dispense as written generic) dispensing.
2. Compare prices at three local pharmacies using GoodRx before filling. Price variation between pharmacies in the same ZIP code commonly exceeds 40%.
3. If insured, confirm formulary tier with your plan's pharmacy benefits manager before the first fill. CMS formulary lookup tools are free and updated monthly.
4. Use HSA or FSA funds for any remaining out-of-pocket cost, including syringes, alcohol swabs, and sharps containers, all of which are FSA/HSA eligible as injection supplies under IRS Publication 502.
5. If cost remains prohibitive after steps 1 to 4, ask the prescriber about 503A compounding options or contact NeedyMeds for local assistance programs.
6. If on a HDHP without an active HSA, opening one before the next plan year and front-loading contributions in January allows full-year pre-tax coverage of testosterone costs from the first fill.

Patients on 100 mg/week testosterone enanthate who follow steps 1 to 4 typically pay $60, $120 per year total for the drug and supplies at 2026 generic pricing at warehouse pharmacies.